[{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase III","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Chemie \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Berlin Chemie \/ Undisclosed"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Aarhus University Hospital | Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Aarhus University Hospital | Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Aarhus \/ Aarhus University Hospital | Leo Pharma"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Oncology","graph2":"Phase II","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ Leo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ Leo Pharma"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase IV","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))"},{"orgOrder":0,"company":"Galician Research Group on Digestive Tumors","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Oncology","graph2":"Phase III","graph3":"Galician Research Group on Digestive Tumors","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galician Research Group on Digestive Tumors \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Galician Research Group on Digestive Tumors \/ Leo Pharma"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Leo Pharma | Sunnybrook Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase IV","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Leo Pharma | Sunnybrook Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"Sunnybrook Health Sciences Centre \/ Leo Pharma | Sunnybrook Research Institute"},{"orgOrder":0,"company":"Denver Health and Hospital Authority","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Denver Health and Hospital Authority","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Denver Health and Hospital Authority \/ Eisai Inc","highestDevelopmentStatusID":"1","companyTruncated":"Denver Health and Hospital Authority \/ Eisai Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Nephrology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Leo Pharma"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Christine Ribic","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Nephrology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Christine Ribic","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Christine Ribic"}]

Find Clinical Drug Pipeline Developments & Deals for Dalteparin sodium

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Galician Research Group on Digestive Tumors

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Galician Research Group on Digestive Tumors

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 23, 2022

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Leo Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 12, 2021

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : Leo Pharma | Sunnybrook Research Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Assistance Publique – Hôpitaux de Paris

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Assistance Publique – Hôpitaux de Paris

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.

                          Product Name : Innohep

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 20, 2015

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Leo Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Centre Hospitalier Universitaire de Saint Etienne

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Centre Hospitalier Universitaire de Saint Etienne

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 09, 2014

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Leo Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 28, 2013

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase IV

                          Sponsor : Christine Ribic

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Bemiparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thrombosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 18, 2013

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Fragmin (Dalteparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Failure, Chronic.

                          Product Name : Fragmin

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 18, 2013

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Academisch Medisch Centrum - Universiteit van Amsterdam

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Academisch Medisch Centrum - Universiteit van Amsterdam

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Hematology

                          Study Phase : Phase IV

                          Sponsor : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Nadroparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 11, 2013

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          University of Aarhus

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          University of Aarhus

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fetal Growth Retardation.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 08, 2011

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase IV

                          Sponsor : Aarhus University Hospital | Leo Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thromboembolism.

                          Product Name : Innohep

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 25, 2010

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank